The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Atherogenic Index of Plasma [Log(Triglycerides/HDL-Cholesterol)]: Theoretical and Practical Implications
Abstract
In individuals with type 2 diabetes, metabolic syndrome, and the combined dyslipidemia, cardiovascular risk is increased by a clustering of risk factors such as abdominal obesity, impaired fasting glucose, increased blood pressure, low HDL-cholesterol (HDL-C), increased triglycerides (TGs), and an increase in small, dense LDL particles. The current increase in the incidence of type 2 diabetes in the population perhaps poses the most urgent cardiovascular risk (1). Although insulin resistance is crucial to the pathogenesis of the disease, the associated atherogenic lipoprotein phenotype considerably enhances the risk. Hence there is an ongoing intense search for a medication capable of modifying the atherogenic lipid profile as well as lowering glucose. Medications of the thiazolidinedione class traditionally used for glycemic control in patients with type 2 diabetes seem to hold promise in this respect. In this issue of Clinical Chemistry, Tan et al. (2) studied the effect of pioglitazone, a thiazolidinedione that reduces insulin resistance, on the atherogenic lipoprotein profile in individuals with type 2 diabetes. Data were obtained from four randomized, placebo-controlled dose–response clinical trials examining the efficacy of therapy with pioglitazone when added to sulfonylurea, metformin, or insulin therapy. To evaluate changes in the lipoprotein profile induced by their therapy, Tan et al. (2) used the atherogenic index of plasma (AIP), calculated as log(TG/HDL-C), with TG and HDL-C expressed in molar concentrations (3). Changes in the AIP of pioglitazone-treated patients were evaluated by a statistical model of single-slope analysis of covariance, and each of the pioglitazone treatments was compared with placebo. All pioglitazone treatment groups had a high AIP at baseline, and pioglitazone treatment significantly decreased the AIP in each study group. Pioglitazone treatment groups had significantly lower AIP than did their respective placebo controls. AIP correlated inversely with insulin sensitivity measures, i.e., the homeostasis model measurement (HOMA-S) and the quantitative insulin sensitivity check index (QUICKI). The study also showed differences between pioglitazone and placebo groups in mean percentage change from baseline. Tan et al. (2) compared the results of AIP analysis with those of a TG/HDL-C ratio analysis used in another study (4). The P values for AIP were consistently lower than those for TG/HDL-C. In addition, normal probability plots showing the relationship of residual error to expected residuals from a gaussian distribution showed a higher correlation for AIP in each study than for TG/HDL-C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor
Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., & Krieger, M. (1996) · Science · doi:10.1126/science.271.5248.518 · Cited by 2,026
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Dobiás̆ová, M., & Frohlich, J. (2001) · Clinical Biochemistry · doi:10.1016/s0009-9120(01)00263-6 · Cited by 1,438
Fasting Triglycerides, High-Density Lipoprotein, and Risk of Myocardial Infarction
Gaziano, J. M., Hennekens, C. H., O’Donnell, C. J., Breslow, J. L., & Buring, J. E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2520 · Cited by 609
Frohlich, J., & Dobiášová, M. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.022558 · Cited by 284
Self-citationGuérin, M., Le Goff, W., Lassel, T. S., Van Tol, A., Steiner, G., & Chapman, M. J. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.2.282 · Cited by 258
Pioglitazone Reduces Atherogenic Index of Plasma in Patients with Type 2 Diabetes
Tan, M. H., Johns, D., & Glazer, N. B. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.031757 · Cited by 203
Murakami, T., Michelagnoli, S., Longhi, R., Gianfranceschi, G., Pazzucconi, F., Calabresi, L., Sirtori, C. R., & Franceschini, G. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.11.1819 · Cited by 201
Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2000) · Diabetologia · doi:10.1007/s001250050023 · Cited by 193
Transfers and exchanges of esterified cholesterol between plasma lipoproteins
Barter, P. J., Hopkins, G. J., & Calvert, G. D. (1982) · Biochemical Journal · doi:10.1042/bj2080001 · Cited by 190
Cited by
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention
Munoz (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6269 · Cited by 760
Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses
Fernández-Macías, J. C., Ochoa-Martínez, A. C., Varela-Silva, J. A., & Pérez-Maldonado, I. N. (2019) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.08.009 · Cited by 458
Salas-Pérez, F., Cuevas-Sierra, A., Cuervo, M., Goni, L., Milagro, F. I., Martínez, J. A., & Riezu-Boj, J. I. (2022) · Epigenetics · doi:10.1080/15592294.2021.1873629 · Cited by 16
Edwards, M., & Loprinzi, P. (2019) · Journal of Physical Activity and Health · doi:10.1123/jpah.2016-0389 · Cited by 16
Metadata
- Authors
- Dobiášová, M.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07-01
- Volume
- 50
- Issue
- 7
- Pages
- 1113-1115
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2163991584
- Cited by
- 419
- References
- 14
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atherogenic Index of Plasma [Log(Triglycerides/HDL-Cholesterol)]: Theoretical and Practical Implications. https://app.cochat.ai/papers/10.1373/clinchem.2004.033175
- The paper
- Dobiášová, M. (2004). Atherogenic Index of Plasma [Log(Triglycerides/HDL-Cholesterol)]: Theoretical and Practical Implications. Clinical Chemistry. https://doi.org/10.1373/clinchem.2004.033175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.